SuperworthFemasys FEMY
- Market cap
- $12.6M
- PE
- n/m
- a loss over the last year
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- 5.5×
- EV/EBIT
- n/m
- a loss over the last year
- Revenue, 12 months
- $2.3M
- +22% on a year ago
- Net margin
- n/m
- outside −100% to 100%
- Free cash flow yield
- −143.9%
Femasys trades at 5.5× sales. Its trailing earnings are negative, so it has no PE. Revenue was $2.3M over the last twelve months, up 22% on a year earlier.
Charts
Financials
| Income statement | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $244.4K−30% | $213.1K−9% | $271.1K−8% | $221.5K−31% | $554.9K+127% | $581.6K+173% | $341.3K+26% | $409.3K+85% | $729.4K+31% | $813.4K+40% | $424.9K+25% | $331.8K−19% | |
| Cost of revenue | $86.2K−34% | $78.3K−8% | $88.5K−16% | $73.1K−34% | $190.8K+121% | $192.4K+146% | $117.3K+33% | $158.2K+116% | $293.8K+54% | $303.1K+58% | $158.6K+35% | $142.4K−10% |
| Gross profit | $158.2K−27% | $134.8K−9% | $182.6K−3% | $148.4K−29% | $364.1K+130% | $389.2K+189% | $224K+23% | $251.1K+69% | $435.6K+20% | $510.3K+31% | $266.3K+19% | $189.4K−25% |
| R&D | $2.1M+26% | $2.1M+63% | $1.8M+15% | $2M+29% | $2.3M+11% | $2.2M+5% | $3M+68% | $1.4M−28% | $1.4M−40% | $1.8M−16% | $1.3M−56% | $1.9M+38% |
| SG&A | $2M+37% | $2.4M+39% | $1.8M+16% | $2.6M+74% | $3.1M+52% | $2.9M+18% | $2.6M+46% | $2.6M+1% | $2.6M−16% | $3.2M+13% | $3.1M+18% | $3.2M+24% |
| −$4.1M+34% | −$4.4M+48% | −$3.5M+14% | −$4.5M+53% | −$5.1M+25% | −$4.7M+6% | −$5.5M+58% | −$3.9M−14% | −$3.7M−29% | −$4.6M−2% | −$4.2M−23% | −$5.1M+32% | |
| Interest expense | $8K+34% | $155.5K+3947% | $361.6K+21524% | $388.3K+196017% | $413.3K+5045% | $440.4K+183% | $459.4K+27% | $491.5K+27% | $532.1K+29% | $408.1K−7% | $176.6K−62% | $186.1K−62% |
| Pre-tax income | −$4M | −$4.4M | −$3.6M | −$4.7M+62% | −$5.4M+35% | −$5.1M+16% | −$5.9M+64% | −$4.6M−2% | −$4.2M−22% | −$3.9M−23% | $846.1K | −$4.5M−3% |
| $0 | $4.3K | $0 | −$1.8K | $1.2K | $10.2K+135% | −$4.2K | $0 | $0 | $5.5K−46% | $0 | $865 | |
| Net income | −$4M+34% | −$4.4M+52% | −$3.6M+22% | −$4.7M+62% | −$5.4M+35% | −$5.1M+16% | −$5.9M+64% | −$4.6M−2% | −$4.2M−22% | −$4M−23% | $846.1K | −$4.5M−3% |
| −$5.20+4% | −$4.20−13% | −$3.40−32% | −$4.20−5% | −$4.80−8% | −$4.40+5% | −$4.60+35% | −$3.18−24% | −$2.00−58% | −$1.20−73% | $0.00 | −$1.33−58% | |
| 754.7K+28% | 1.1M+81% | 1.1M+83% | 1.1M+70% | 1.1M+47% | 1.1M+7% | 1.3M+16% | 1.4M+30% | 2.1M+85% | 3.1M+175% | 3.9M+211% | 3.4M+133% |
Revenue: Q1 FY20 and Q1 FY21: 6 months less the 3 months printed beside them.
Cost of revenue: Q1 FY20 and Q1 FY21: 6 months less the 3 months printed beside them.
Gross profit: Q1 FY20 and Q1 FY21: 6 months less the 3 months printed beside them. 11 periods, Q4 FY23 to Q2 FY26: not printed by the filing, worked out from its own lines.
R&D: Q1 FY20 and Q1 FY21: 6 months less the 3 months printed beside them.
SG&A: Q1 FY20 and Q1 FY21: 6 months less the 3 months printed beside them.
Operating income: Q1 FY20 and Q1 FY21: 6 months less the 3 months printed beside them.
Interest expense: Q1 FY20 and Q1 FY21: 6 months less the 3 months printed beside them.
Pre-tax income: Q1 FY20 and Q1 FY21: 6 months less the 3 months printed beside them.
Income tax: Q1 FY20 and Q1 FY21: 6 months less the 3 months printed beside them.
Net income: Q1 FY20 and Q1 FY21: 6 months less the 3 months printed beside them.
EPS, diluted: 8 periods, Q1 FY20 to Q4 FY25: quarter's net income to common over its shares, to the cent.
Diluted shares: Q1 FY20: share-days: the 6-month average less the second quarter's. 6 periods, Q4 FY20 to Q4 FY25: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Medical - Instruments & Supplies nearest Femasys' size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| FEMYFemasys | $12.6M | n/m | n/a | 5.5× | +22% | n/m | |
| NEPHNephros | $38.3M | 22.1× | 28.4× | 1.9× | +24% | 8.4% | |
| APTAlpha Pro Tech | $56.7M | 13.6× | 14.8× | 0.9× | +6% | 6.8% | |
| KEQUKewaunee Scientific | $94.9M | 11.9× | 13.7× | 0.3× | +5% | 3.0% | |
| Peer median | $56.7M | 13.6× | 14.8× | 0.9× | +6% | 6.8% |
More on Femasys
Each number over time
Its groups
About
- Industry
- Medical - Instruments & Supplies
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .